Australia Forges Gene Therapy Hub with Key UK Partnership

SYDNEY, March 18, 2026 – Australia has taken a monumental step towards becoming a global force in advanced medicine, as its first commercial viral vector manufacturer secures a critical technology deal with a world-leading British firm. Viral Vector Manufacturing Facility Pty Ltd (VVMF), a trailblazing Australian entity, today announced a strategic licensing agreement with UK-based Oxford Biomedica (OXB), a global pioneer in cell and gene therapy.

The five-year agreement provides VVMF with a non-exclusive license to OXB's proprietary inAAVate™ platform for adeno-associated viral vectors (AAV) and includes an option to license its LentiVector™ platform. This collaboration is set to turbocharge VVMF's operational capabilities, positioning Australia as a key manufacturing hub for the rapidly expanding Asia-Pacific (APAC) cell and gene therapy market.

Bolstering Australia's Biotech Ambitions

This partnership is more than a simple business transaction; it represents the cornerstone of a national strategy to build a sovereign and globally competitive biotechnology sector. Established with a significant A$134.5 million investment from the New South Wales Government, VVMF stands as Australia's only dedicated Contract Development and Manufacturing Organisation (CDMO) for viral vectors—the critical delivery vehicles used in groundbreaking cell and gene therapies.

Located in Sydney’s Westmead Health and Innovation Precinct, VVMF is poised to bridge a crucial gap in the local and regional biomanufacturing ecosystem. Until now, Australian researchers and biotech firms often had to look overseas for the complex and highly specialized process of producing GMP-grade viral vectors for clinical trials and commercial products. This agreement aims to change that dynamic entirely.

Australia’s appeal is magnified by a suite of powerful incentives. The federal government's R&D tax incentive offers a rebate of up to 43.5%, significantly lowering the financial barrier for biopharma innovation. This is complemented by a globally respected regulatory framework overseen by the Therapeutic Goods Administration (TGA), which has been actively streamlining its approval pathways for advanced therapies. Combined with geopolitical stability and robust intellectual property laws, the nation presents a compelling case for investment.

Unlocking a $40 Billion Regional Market

The timing of this partnership is critical, aligning with explosive growth in the APAC cell and gene therapy sector. Market analysts project the regional market to soar from approximately US$4.59 billion in 2024 to nearly US$40 billion by 2034, reflecting a compound annual growth rate of over 24%. This surge is driven by rising investments, an increasing prevalence of cancers and rare genetic disorders, and a strong pipeline of innovative therapies.

Viral vectors are the engine of this growth, with technologies like lentiviral vectors commanding a dominant market share of over 40%. By securing access to OXB's leading platforms, VVMF is positioning itself to capture a significant portion of this demand. The deal allows VVMF not just to serve its domestic market but to act as a launchpad for international clients looking for a stable and efficient manufacturing partner in the region.

While global giants like WuXi AppTec and Catalent have a strong presence in Asia, VVMF's focused, state-of-the-art facility, backed by Australian government support and now armed with OXB's technology, carves out a unique and competitive niche.

The Power of Proven Platforms

For biopharma companies, the journey from a laboratory concept to a patient-ready therapy is fraught with technical challenges, regulatory hurdles, and immense financial risk. Access to standardized, high-quality manufacturing platforms is one of the most effective ways to de-risk this process.

OXB's platforms are industry-validated and have been honed over 30 years of pioneering work in the field. The LentiVector™ platform is renowned for its ability to carry large genetic payloads and efficiently transduce a wide variety of cell types, making it a workhorse for many ex vivo gene therapies like CAR-T for cancer. The inAAVate™ platform, focused on AAV vectors, is prized for its strong safety profile and efficacy in delivering therapies directly into the body (in vivo) for a range of genetic diseases.

By licensing these technologies, VVMF bypasses years of internal development and process optimization. It can offer its clients a faster, more reliable, and capital-efficient path to the clinic. Stephen Thompson, CEO of VVMF, emphasized this advantage, stating, “Access to the OXB platforms gives us a strong foundation as we continue to build our capabilities, leveraging OXB’s expertise and global brand recognition to establish a leadership position in the APAC region. The collaboration will help us accelerate operational readiness and ensure our processes are aligned with recognised industry standards.”

A Strategic Alliance for Global Reach

The agreement is a textbook example of a symbiotic partnership. For VVMF, it provides instant credibility and access to world-class technology. For OXB, it represents a shrewd, capital-light expansion into a high-growth market, generating licensing revenue while extending the reach of its proprietary platforms.

Dr. Sébastien Ribault, Chief Business Officer of OXB, highlighted the strategic value for his company. “This agreement is a strong endorsement of OXB’s position as a world-leading viral vector CDMO,” he said. “Partnering with VVMF not only gives us a strategic foothold in Australia but also creates a launchpad to serve clients across the APAC region, further strengthening the global foundation for reliable AAV and lentiviral vector production.”

This model of technology licensing and collaboration is becoming increasingly vital for the cell and gene therapy industry. It allows for the decentralization of manufacturing, bringing production closer to patient populations while ensuring that global quality standards are maintained. By enabling local partners like VVMF, the entire global supply chain becomes more resilient and capable of meeting the escalating demand for these life-changing medicines. The ultimate beneficiaries of this strategic alliance will be the patients across Australia and the Asia-Pacific who may gain faster access to the next generation of medical treatments.